Physician
Hematology
Dr. Paul E. Goss, MD
|
|
Give Review
Paul Goss practices Hematology. Paul Goss is a published doctor as well. He has 102 publications published. The latest was: Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure. Paul E. Goss accepts all Medicare patients.
Publications
- Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
- Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
- Progress and remaining challenges for cancer control in Latin America and the Caribbean.
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HE...
- Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
- Reply to P. Niravath et al.
- Breast cancer in China.
- Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
- Challenges to effective cancer control in China, India, and Russia.
- Intermittent Letrozole Therapy for Metastatic Breast Cancer: Case Reports and Literature Review.
- Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study.
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-g...
- Reply to E. Esin et al.
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker.
- Mammographic breast density response to aromatase inhibition.
- Planning cancer control in Latin America and the Caribbean.
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
- Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
- Breast cancer in Mexico: a growing challenge to health and the health system.
- Denosumab and the current status of bone-modifying drugs in breast cancer.
- Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
- Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover.
- Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC...
- Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the ...
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
- Extended adjuvant endocrine therapy in breast cancer: current status and future directions.
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
- Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup...
- Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
- Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
- Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
- The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
- National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
- Lapatinib-associated toxicity and practical management recommendations.
- Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
- Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
- Breast cancer adjuvant endocrine therapy.
- Mammographic breast density and race.
- TEACH: Tykerb evaluation after chemotherapy.
- Aromatase inhibitors and bone health in women with breast cancer.
- Lapatinib: current status and future directions in breast cancer.
- Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
- Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to N...
- Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
- Aromatase inhibitor withdrawal response in metastatic breast cancer.
- Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
- Bone loss with exemestane: Is the jury still out?
- Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
- Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer.
- Advances in adjuvant hormonal therapy for postmenopausal women.
- Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
- Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
- Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- Prevention strategies with aromatase inhibitors.
- Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
- Emerging role of aromatase inhibitors in the adjuvant setting.
- Specific homeodomain-DNA interactions are required for HOX11-mediated transformation.
- Prevention of breast cancer using SERMs and aromatase inhibitors.
- Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
- Evolving perspectives in contralateral breast cancer.
- Examination of POU homeobox gene expression in human breast cancer cells.
- Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.
- Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer.
- Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
- Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade.
- Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter.
- Breast cancer in women following supradiaphragmatic irradiation for Hodgkin''s disease.
- The importance of a family history of breast cancer in predicting the presence of a BRCA mutation.
- High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases.
- Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter.
- Risks versus benefits in the clinical application of aromatase inhibitors.
- Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.
- Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breas...
- The effects of type of surgery and time on psychological adjustment in women after breast cancer treatment.
- Characterization of a novel silencer element in the human aromatase gene PII promoter.
- Aromatase inhibitors in the treatment and prevention of breast cancer.
- Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin''s lymphoma.
- A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism an...
- A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
- Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
- Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Insti...
- Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
- Breast cancer in women < or = 35 years: review of 1002 cases from a single institution.
- Estrogen and the risk of breast cancer.
- Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q.
- DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin''s lymphomas.
- A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin''s lymphoma in elderly patients.
- Aromatase inhibitors and their potential clinical significance.
- Aromatase inhibitors and the treatment of breast cancer.
- Breast cancer risk following irradiation for Hodgkin''s disease.
- The role of COX-2 inhibition in breast cancer treatment and prevention.
- Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a ...
- Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
- Competing Risks in Low-Risk Breast Cancer.
- Management of recurrent locoregional breast cancer: oncologist survey.
- Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Schools
The University Of Witwatersrand Med School
University Toronto Health Network
Doctors Specialties
- Hematology
Accepted Insurances
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184606394 |
| Last Name Of The Provider | GOSS |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Robert D. Sackstein, MD |
|
|
Dr. Barbara E. Bierer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lourdes M. Mendez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin L. Ebert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen E. Sallan, MD
This Doctor is OpenDoctor Recommended.
|